Akari Therapeutics Plc · NASDAQ:AKTX
Akari Therapeutics — Merger or Acquisition (March 2024)
22 slides from Akari Therapeutics's merger presentation, Mar 5, 2024
Slide 1: Akari Therapeutics Company Presentation March 2024
Akari Therapeutics Company Presentation March 2024
Slide 2: Forward-looking statements
2 This communication relates to the proposed transaction pursuant to the terms of the Agreement and Plan of Merger (the “Merger Ag reement”), by and among Akari Therapeutics, Plc, a public company limited by shares incorporated in England and Wales (“ Akari ”),, Pegasus Merger Sub, Inc., a Delaware
Slide 3: Additional Disclaimers
3 Additional Disclaimers No Offer or Solicitation This communication is not intended to and shall not constitute an offer to subscribe for, buy or sell or the solicitation of an offer to subscribe for, buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale
Slide 4: Definitive Agreement for Merger of Equals with Peak Bio
4 DEFINITIVE AGREEMENT FOR MERGER OF EQUALS WITH PEAK BIO
Slide 5: Akari/Peak Bio Definitive Agreement/Merger of Equals
Akari/Peak Bio Definitive Agreement/Merger of Equals 5 Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit Following closing, the combined company will have an expanded pipeline tha
Slide 6: Akari Overview
6 AKARI OVERVIEW
Slide 7: Akari Overview
Akari Overview Nomacopan is a unique asset inhibiting 2 co - dependent, proinflammatory targets: complement C5 and leukotriene B4 (LTB4) 7 Potential for use in several diseases; commercial flexibility due to multiple routes of administration (subcutaneous, topical, intravitreal, IV) 1. Novel Complem
Slide 8: Complement Technologies Continue to Garner Significant Investment
Complement Technologies Continue to Garner Significant Investment 8 Astra Zeneca / Alexion Company* Company Value Status/Phase Indications $39 billion completed acquisition Soliris ® / Ultomiris ® PNH, aHUS , gMG , NMOSD / PHN, aHUS , gMG Tavneos ® Amgen / ChemoCentryx ANCA - Vasculitis $7.70 billio
Slide 9: Nomacopan inhibits two pathways that can cause damaging inflammation
Nomacopan inhibits two pathways that can cause damaging inflammation, while preserving important immune functions (such as opsonization) • C5a, LTB4 and MAC act jointly on neutrophils, macrophages and other cell types that can cause inflammation and damage • Signaling interplay between C5 and LTB4 m
Slide 10: Pipeline Programs
Pipeline Programs AKARI Discovery Pre-Clinical © Phase 1 Phase2 Phase 3 redalendiths fsialin Neue ean P| | | dy ¢ Geographic atrophy (GA) Nomacopan e HSCT-TMA
Slide 11: Previous Areas of Clinical Development, Including PNH and BP
• In addition to current areas of focus, Akari has conducted clinical research in several other areas, including Phase 2/3 clin ica l trials of subcutaneous nomacopan for treatment of bullous pemphigoid (BP) and paroxysmal nocturnal hemoglobinuria (PNH) • This research set a solid foundation for the
Slide 12: Akari Development Programs
12 AKARI DEVELOPMENT PROGRAMS
Slide 13: Nomacopan in HSCT-TMA
13 NOMACOPAN IN HSCT - TMA
Slide 14: Nomacopan May Be the First Treatment for HSCT-TMA
14 • HSCT - TMA is a rare but serious complication of HSCT involving complement activation, inflammation, tissue hypoxia and blood clots, leading to progressive organ damage and death • Graft versus host disease is commonly present in patients with severe HSCT - TMA 1 • Mortality is 80% across adult
Slide 15: Clinical Trial Patient Case Study
15 Clinical Trial Patient Case Study Presented at Two Transplantation and Cellular Therapy Meetings A patient with severe pediatric HSCT - TMA, which typically involves multi - organ failure and other acute consequences, was discharged home from the hospital following treatment with nomacopan • 6 -
Slide 16: Geographic Atrophy (GA)
16 GEOGRAPHIC ATROPHY (GA)
Slide 17: Geographic atrophy overview and prevalence
17 • Geographic atrophy (GA) manifests as a chronic progressive degeneration of the macula, which occurs during late - stage dry age - related macular degeneration (dAMD) and can lead to irreversible vision loss • Approximately 5 million people worldwide are affected, 1,2 with nearly 1 million in th
Slide 18: KOL Insights on GA Treatment Landscape and Unmet Needs
KOL Insights on GA Treatment Landscape and Unmet Needs 18 “ ” Despite FDA approvals of the first treatments for GA, there are still significant unmet needs. It’s important that we reduce the frequency of therapy, which must be administered through intravitreal injection into the eye. In addition, tr
Slide 19: PAS-Nomacopan May Provide 3 Key Benefits
1. Complement C5 inhibition to slow GA progression Frequent needle injections into the back of the eye, a source of fear, discomfort and disruption for patients 3 ; potential for 4 or fewer injections with PAS - nomacopan each year LTB4 inhibition may prevent VEGF - A overexpression, a key driver of
Slide 20: Long-Acting PAS-Nomacopan Has Potential to Extend Intravitreal Dose Interval
Long - Acting PAS - Nomacopan Has Potential to Extend Intravitreal Dose Interval to 3 Months or Longer 1 10 100 1,000 10,000 0 20 40 60 80 100 120 PAS - nom concentration vitreous ( µg/mL) Time (days) 0.05mL PAS600-nomacopan (20 mg/mL) 0.05mL PAS600-nomacopan (60 mg/mL) Long - Acting PAS - Nomacopan
Slide 21: PAS-Nomacopan Decreased VEGF Levels in a Pre-Clinical Model
PAS - Nomacopan Decreased VEGF Levels As Effectively As An Anti - VEGF Antibody In a Pre - Clinical Model V E G F ( p g / m l ) S a l i n e n o m a P A S - n o m a a n t i - V E G F H e a l t h y c t 0 100 200 300 p=0.044 p=0.048 Effect of PAS - nomacopan on VEGF levels in a standard pre - clinical
Slide 22: Thank You
22 THANK YOU
Akari Therapeutics — Merger or Acquisition (March 2024) on 6ix